OCM
BBIO icon

Ovata Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Ovata Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-20,000
Closed -$332K – 23
2023
Q1 		$332K Buy
+20,000
New +$233K 0.14% 25

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Ovata Capital Management's BBIO Position: Q2 2023 in Review

Ovata Capital Management sold out of BridgeBio Pharma (BBIO) in Q2 2023, closing a stake of 20,000 shares — an estimated $332K sold.

Ovata Capital Management first reported a position in BBIO in Q1 2023 and held it in 1 quarter. The position peaked at $332K in Q1 2023. 197 funds tracked by Wall St. Rank hold BBIO as of Q2 2023.

  • Ovata Capital Management reported no remaining BridgeBio Pharma position as of Q2 2023 after selling out during the quarter.
  • Ovata Capital Management sold 20,000 BridgeBio Pharma shares in Q2 2023, an estimated $332K.
  • Ovata Capital Management first reported a position in BridgeBio Pharma in Q1 2023 and held it in 1 quarter.
  • Ovata Capital Management's BridgeBio Pharma position peaked at $332K in Q1 2023.
  • 197 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2023.

Based on Ovata Capital Management's 13F filing for Q2 2023, filed 4 Aug 2023.